Cowen analyst Phil Nadeau downgraded Frequency Therapeutics to Market Perform from Outperform.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FREQ:
- Frequency Therapeutics Craters into Penny Stock Territory
- Frequency Therapeutics reports CEO David Lucchino is on temporary medical leave
- Frequency announces FX-332 study misses endpoint, to reduce personnel by 55%
- Frequency Therapeutics doses first patient in FX-345 study
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue